Overcoming mechanisms of therapeutic resistance in pancreatic ductal adenocarcinoma

克服胰腺导管腺癌的治疗耐药机制

• 批准号: 10629062
• 负责人: TONY R. HUNTER
• 金额: $ 295.32万
• 依托单位: SALK INSTITUTE FOR BIOLOGICAL STUDIES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-06 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10629062
• 关键词: Automobile Driving; Autophagocytosis; Biology; Biometry; Biostatistics Core; CA-19-9 Antigen; Cancer Etiology; Cell Communication; Cell Survival; Cells; Cessation of life; Chemoresistance; Clinical; Coculture Techniques; Coupled; Cues; DNA Damage; Desmoplastic; Development; Drug Delivery Systems; Drug resistance; Epidermal Growth Factor Receptor; Epigenetic Process; Fibroblasts; Genome; Goals; Growth; HDAC1 gene; Heterogeneity; Histone Deacetylase; Histone Deacetylase Inhibitor; Human; Hypoxia; Immune; Immune checkpoint inhibitor; Immunotherapy; Individual; Inflammatory; Informatics; LIF gene; Macrophage; Macrophage Activation; Malignant Neoplasms; Malignant neoplasm of pancreas; Mediating; Metabolic; Metabolism; Modeling; Mus; Mutation; Nature; Nutrient Depletion; Nutrient availability; Organoids; Outcome; Pancreatic Ductal Adenocarcinoma; Paracrine Communication; Pathway interactions; Patients; Polysaccharides; Post-Translational Protein Processing; Production; Refractory Disease; Regulation; Research Personnel; Research Project Grants; Research Support; Resistance; Resource Sharing; Role; STAT3 gene; Sampling; Signal Pathway; Signal Transduction; Specimen; Stress; Stromal Cells; Survival Rate; System; Testing; Therapeutic; Toxic effect; Treatment Efficacy; Tumor Promotion; Vascularization; cell type; checkpoint inhibition; chemotherapy; combinatorial; cytokine; digital; epigenome; glycosylation; immunogenic cell death; improved; inhibition of autophagy; inhibitor; innovation; interest; mortality; mouse model; nanoparticle drug; neoplastic cell; novel; novel therapeutics; paracrine; programs; resistance factors; resistance mechanism; response; single cell analysis; stem; support network; synergism; targeted treatment; therapy outcome; therapy resistant; treatment response; treatment strategy; tumor; tumor growth; tumor microenvironment; tumorigenic

PROJECT SUMMARY – Overall While mortality rates for many cancers are declining, pancreatic ductal adenocarcinoma (PDA) remains a highly lethal malignancy with the worst 5-year survival rate of the common malignancies. Unfortunately, current therapies are largely ineffective in PDA, an outcome attributed in large part to therapeutic resistance. The highly fibrotic and poorly vascularized tumor microenvironment (TME) restricts both nutrient availability and drug delivery, and provides pro-survival and immunosuppressive cues. These limitations create energy stresses that drive metabolic adaptations to support tumor growth and therapeutic resistance. Moreover, the hyperactivation of pro-survival and resistance pathways in tumor and stromal cell types results in an integrated resistance network. The induction of these pathways is orchestrated by cell-to-cell communications within the TME, including aberrant glycosylation (CA-19-9) and the secretion of immunosuppressive and pro-survival paracrine factors, such as Leukemia Inhibitory Factor (LIF) from cancer-associated fibroblasts (CAFs). In addition, cells adapt to the hypoxic, nutrient-depleted TME by upregulating cell type-specific survival programs, including autophagy. Ultimately, to support and respond to these signaling and metabolic programs, both the tumor and stromal cell epigenomes are reprogrammed, leading to cellular heterogeneity and plasticity that restricts durable therapy responses. Each of these programs promote resistance to a broad range of therapeutics, including chemotherapies, targeted therapies, and immune checkpoint inhibitors. The central hypothesis of this program is that pancreatic cancer has co-opted an integrated network of epigenetic programs, paracrine signaling pathways, and metabolic adaptations to promote tumor survival and therapeutic resistance. Building upon the investigators’ complementary expertise in epigenetics, cell signaling, and metabolic adaptations, as well as common interests in pancreatic cancer, this program seeks to understand the interactions that hinder PDA therapeutic responses, with the ultimate goal of identifying vulnerabilities that can be exploited and targeted to overcome drug resistance. Importantly, the program will utilize advanced mono- and co-culture organoid systems, cutting-edge mouse models, novel therapeutics, single-cell approaches, and human clinical specimens to delineate the contributions of both tumor cells and their stromal support network to therapeutic resistance. Moreover, proposed cooperative and innovative approach will reveal how these resistance nodes are integrated and can be targeted to improve therapeutic outcomes in PDA.

项目概要-总体 虽然许多癌症的死亡率正在下降，但胰腺导管腺癌（PDA）仍然是一个高度危险的疾病。 常见恶性肿瘤中5年生存率最低的致死性恶性肿瘤。不幸的是，目前 治疗在PDA中很大程度上是无效的，这一结果在很大程度上归因于治疗抗性。高度 纤维化和血管化不良的肿瘤微环境（TME）限制了营养的利用和药物治疗， 递送，并提供促存活和免疫抑制信号。这些限制产生了能量压力， 驱动代谢适应以支持肿瘤生长和治疗抗性。此外，超激活 肿瘤和基质细胞类型中促生存和耐药途径的整合导致了 网络这些通路的诱导是由TME内的细胞间通讯协调的， 包括异常糖基化（CA-19-9）和免疫抑制和促存活旁分泌 因子，如来自癌症相关成纤维细胞（CAF）的白血病抑制因子（LIF）。此外，细胞 通过上调细胞类型特异性存活程序来适应缺氧、营养耗尽的TME，包括 自噬最终，为了支持和响应这些信号传导和代谢程序，肿瘤和 基质细胞表观基因组被重新编程，导致细胞异质性和可塑性，限制了持久的细胞分化。 治疗反应。这些项目中的每一个都促进了对广泛的治疗药物的耐药性，包括 化疗、靶向治疗和免疫检查点抑制剂。 这个项目的中心假设是胰腺癌已经选择了一个整合的网络 表观遗传程序，旁分泌信号通路和代谢适应，以促进肿瘤 存活和治疗抗性。基于研究人员在表观遗传学方面的互补专业知识， 细胞信号，代谢适应，以及胰腺癌的共同利益，该计划旨在 了解阻碍PDA治疗反应的相互作用，最终目标是确定 这些脆弱性可以被利用并有针对性地克服耐药性。重要的是，该计划将 利用先进的单一和共培养类器官系统，尖端的小鼠模型，新型疗法， 单细胞方法和人类临床标本来描述肿瘤细胞及其 基质支持网络对治疗耐药性。此外，拟议的合作和创新办法将 揭示了这些耐药节点是如何整合的，并可以有针对性地改善PDA的治疗效果。